BridgeBio Oncology Therapeutics, Inc. (BBOT)
| Market Cap | 704.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -134.04M |
| Shares Out | 80.03M |
| EPS (ttm) | -4.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 461,701 |
| Open | 8.77 |
| Previous Close | 8.79 |
| Day's Range | 8.66 - 9.33 |
| 52-Week Range | 8.08 - 14.87 |
| Beta | 0.51 |
| Analysts | Strong Buy |
| Price Target | 24.00 (+172.73%) |
| Earnings Date | May 26, 2026 |
About BBOT
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for BBOT stock is "Strong Buy." The 12-month stock price target is $24.0, which is an increase of 172.73% from the latest price.
News
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development exp...
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycem...
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway maligna...
BridgeBio Oncology Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Three clinical programs targeting RAS and PI3K pathways are advancing, with all major readouts expected in the second half of 2026. Early data show strong efficacy and safety, especially for the KRAS G12C and pan-KRAS inhibitors, and multiple combination studies are underway.
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS muta...
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway. Announced encouraging preliminary ...
BridgeBio Oncology Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Three in-house developed assets target RAS-driven tumors with novel on/off inhibition and selective pathway modulation. Early clinical data show strong efficacy and safety, especially in combination settings, with key data readouts expected in the second half of the year.
BBOT to Participate in Upcoming Investor Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignan...
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignan...
BridgeBio Oncology Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Three oncology programs showed strong efficacy and safety: 8520 led to high response rates and durable benefit in NSCLC, 818 demonstrated pan-KRAS activity with low toxicity, and 203 achieved target engagement without hyperglycemia. Internal combinations are prioritized, with more data expected in 2026.
BridgeBio Oncology Therapeutics Transcript: Study Update
Promising early clinical data for three RAS pathway inhibitors show high response rates, durable efficacy, and favorable safety profiles in difficult-to-treat cancers. Combination strategies with standard therapies are advancing, with key data updates expected in 2026.
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs
BBO-8520 monotherapy in patients with KRAS G12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients el...
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignan...
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignan...
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignan...
BridgeBio Oncology Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Three clinical programs targeting RAS and PI3K alpha advanced in 2025, supported by a $380M de-SPAC merger. Key data readouts for all programs are set for 2026, with strategic partnering and portfolio prioritization planned based on results.
BridgeBio Oncology Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Three clinical-stage oncology programs targeting RAS and PI3K-alpha are advancing, with BBO-8520 showing strong early efficacy and safety, and additional data from all programs expected in 2025–2026. Financial resources are sufficient to support development through key milestones.
BBOT to Participate in Upcoming December Investor Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignan...
BridgeBio Oncology Therapeutics Transcript: Jefferies London Healthcare Conference 2025
The company has rapidly advanced three RAS- and PI3Kα-focused assets into phase I, secured over $800 million in funding, and expects pivotal clinical data readouts in 2025. Early results show strong efficacy and safety, with innovative mechanisms targeting key oncogenic pathways.
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS com...
BBOT to Participate in the Jefferies Global Healthcare Conference in London
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignan...
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignan...
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignan...